Clay Siegall, CEO and Chief Founder of Seattle Genetics in Washington DC

Clay Siegall is the CEO and Chief Founder of Seattle Genetics since its establishment in 1998. He is also the chairperson of the board of directors in his company. Dr. Siegall graduated from Washington University with a Ph.D. in Genetics and a B.S. in zoology from the University of Maryland. Clay Siegall holds many other titles in different organizations that he has worked with. In 2011, under his leadership, Seattle Genetics built an Antibody-based cancer therapy that was approved by the Food and Drug Administration (FDA) in U.S. His company operates with more than 675 million dollars since 2001.

Between 1991 and 1997, Dr. Siegall was operating as a pharmacist in the Research Institution in Bristol-Myers. Before then he worked with National Cancer Institute between 1988 and 1991. He is also in the Board of Directors of Alder Biopharmaceuticals, which is a private company. Above all, Dr. Clay Siegall is an author, and he has managed to publish more than 70 books.

Seattle Genetics is ranked as the largest biotech in Washington D.C. The company has over 900 employees and boasts a market value of nearly 10 million dollars. The company is aimed at expanding and creating more work for young and learned youths. It expects to add 200 employees as we speak. The Chief Founder and Director Dr. Siegall is passionate about the company, and the pipeline of drugs they produce is a sure deal that he is not going to sell the biotech firm. Recently, Dr. Siegall has opened an office in Switzerland to help Seattle Genetics to perform its international marketing efficiently.

Dr. Clay Siegall is focused on drug production and other complexities that may be existing in the international market. He is ready to fill the gap of drug scarcity and therapy across the globe. In February 2017, Dr. Siegall spent 2 million dollars to get global rights to commercialize cancer drug that was developed by the Jersey-based firm. Thereafter, Dr. Siegall managed the case and was in a position to deliver a new cancer drug into the global market.

The company has grown in the last 18 years from a share of 20 dollars to 66 dollars. It has also improved from a capital of 418 million dollars to 46% by 2014. The company has concentrated on producing an antibody drug conjugate also known as ADC. Other than ADC, there are other drugs that the company is largely producing that include Adcetris, number 33A, 22ME and LIV1.

Leave a Reply

Your email address will not be published. Required fields are marked *